Updated: 4 hours 23 min ago
Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials who are stuck trying not to be over- or underprepared for a potential crisis that may never come.
Cybernet Manufacturing, maker of medical-grade computers, tablets and monitors, has unveiled a new, large touchscreen designed to protect against the growth of infection-causing organisms and limit their spread throughout a hospital.
A startup has raised $12 million to fund its real-time system for monitoring patients undergoing dialysis at home and calling in potential complications.
Digital diabetes maven One Drop has brought on Sanofi’s former U.S. head of tech-enabled diabetes care to help guide its commercialization efforts as well as a new vice president to lead its work in behavior-centered design.
Medtronic is looking to augment not only its work in robotic surgery, but efforts across all of its procedural offerings through the acquisition of Digital Surgery, the London-based makers of data analytics, artificial intelligence and training programs for the operating room.
The FDA has cleared the world’s first portable MRI system, designed to be wheeled to a hospital bedside for scanning a patient’s head and brain.
By measuring the minuscule motions of the human eye—and tracking the movements of the retina on a cellular level—a startup hopes to open new windows into a person’s neurological health.
Pediatric digital therapeutics developer Cognoa has teamed up with Autism Learning Partners, a specialized treatment provider, to put its app in the hands of parents to help track their children’s development.
Outset Medical has raised $125 million to accelerate the U.S. commercialization of its all-in-one hemodialysis machine. The former Fierce 15 winner previously raised $132 million for its U.S. expansion in August 2018.
Long-troubled Valeritas, manufacturers of a wearable, disposable insulin pump, has filed for Chapter 11 bankruptcy as part of a plan to hand off its business to the specialty drugmaker Zealand Pharma, through a court-supervised sale.
The FDA approved the first artificial intelligence-powered software designed to assist and guide medical professionals without any specialized training through the steps of a cardiac ultrasound exam—one of the most common tools used to diagnose heart disease.
By using a fluorescent dye that binds to cancer cells and makes them glow during surgery, researchers believe they can help make sure every piece of a person’s tumor has been removed. Now, researchers have launched phase 3 trials of the intravenous dye, dubbed OTL38, in lung and ovarian cancers with a boost from previous FDA Fast Track and orphan designations.